WILLIAMS AND JENSEN, PLLC for PFIZER
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Medicare payment issues including the Independent Payment Advisory Board (IPAB) and Medicaid issues. Medicare Part D. CMMI Medicare Part B Demonstration.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER | — |
| KARINA LYNCH | — |
| GEORGE OLSEN | — |
Trade (domestic/foreign) TRD
IP protections related to trade agreements; trade policies impacting pharmaceutical development.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER W HATCHER | — |
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER New | Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep. Cantor; Sr Policy Adv, Republican Whip, Rep. Cantor; Sr Policy Adv, Majority Whip, Rep. Blunt; Prof Staff House Committee on E & C; Sr LA to Rep. Cox |
| KARINA LYNCH | — |
Budget/Appropriations BUD
Labor - HHS Appropriations FY 2020; Policies impacting Medicare Part D.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN | COS, Rep Van Hilleary and Majority Whip |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER | Shrd Employee, Ofc of the Speaker & Ofc of VA 7; Sr Policy Adv, Majority Leader, Rep Cantor; Sr. Policy Adv, Rep Whip, Rep Cantor; Sr. Policy Adv, Majority Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr. LA to Rep Chris Cox |
Taxation/Internal Revenue Code TAX
Tax issues affecting the pharmaceutical industry including international tax. Implementation of the Tax Cuts and Jobs Act (P.L. 115-97).
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER W HATCHER | — |
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
| KARINA LYNCH | — |
| GEORGE OLSEN | — |
Health Issues HCR
General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; Medicare Part D; Federal preemption for prescription drugs; drug importation; and drug shortages.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER | — |
| KARINA LYNCH | — |
| MELINDA M MAXFIELD | — |
| GEORGE OLSEN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.